"Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" Published

2011-11-05 06:57:52 - Recently published research from GlobalData, "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018", is now available at Fast Market Research

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house

analysis by GlobalData's team of industry experts.

Full Report Details at
- www.fastmr.com/prod/269487_osteoporosis_therapeutics_pipeline_as ..

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone. The recent launch of Prolia (denosumab), a monoclonal antibody from the therapeutic class RANKL inhibitor, has also opened new avenues for the treatment of osteoporosis with improved safety, efficacy and compliance to medication by the patient. The bisphosphonates are the preferred drug for treatment and are used as the first line of therapy for the treatment of osteoporosis. The expected moderate growth can be attributed to the increase in awareness among people regarding osteoporosis, especially among females about postmenopausal osteoporosis (PMO) which contributes the largest number of patient pool to osteoporosis. GlobalData also predicts that an increase in the patient population as a consequence of the ageing population will drive the moderate growth in the osteoporosis therapeutics market. The modest growth observed in the osteoporosis therapeutics market during 2010 to 2018 can also be attributed to the expected launch of pipeline products such as Odanacatib (MK 0822), NB S101 during the late forecast period. The patent expiry of Actonel (risedronate sodium), Boniva (ibandronate), Reclast (zoledronic acid), Evista (raloxifene) and Protelos (strontium malonate) during 2012 to 2014 will act as the major barriers for the growth of osteoporosis therapeutics market during the forecast period. The impending patent expiry of Boniva in 2012; Actonel and Reclast in 2013; and Evista in 2014 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The sales growth will also be affected by Fosamax (alendronate) generics, which lost its patent exclusivity in 2008. The main treatment options available in the osteoporosis therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate) among others.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes -

* Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
* Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor
* Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.
* Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis therapeutics market in future.
* About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.